Clene Inc. CLNN
Set alert
At close · Oct 30
After hours · Oct 30, 7:10 PM ET
- YTD
- -34.75%
- 1 year
- -61.70%
- Open
- 3.75
- Prev close
- 3.90
- Mkt cap
- 54.44M
- Vol
- 47.27K
- Avg vol
- 105.24K
- EPS
- -3.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.75
- High
- 3.95
- Forward P/E
- -1.34
- Beta
- 0.41
- Short ratio
- 1.90
- Inst. own
- 12.91%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 5.00
- 200-d avg
- 6.14
- 1y target
- 45.17
News
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
1 week ago benzinga.com
Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
3M shares rose 4.4% premarket after expanding its Amazon data-center deal, including a $521.4M stock warrant; other stocks saw sharp moves.
-
1 week ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
1 week ago globenewswire.com
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced…
2 weeks ago defenseworld.net
Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN)
Clene (NASDAQ: CLNN - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two…
1 month ago marketbeat.com
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision
Clene NASDAQ: CLNN said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for…
1 month ago defenseworld.net
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of “Moderate Buy” from Brokerages
Clene Inc. (NASDAQ: CLNN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat.com reports. One analyst has…
1 month ago globenewswire.com
Clene to Present at Upcoming Investor Conferences
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the…
1 month ago globenewswire.com
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the closing of a registered direct offering of…
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…
-
1 month ago benzinga.com
Datavault AI Receives Initial Purchase Order For $100M Of Its $QEST Tokenization Services
Nathaniel Bradley, Co-Founder and CEO of Datavault AI Inc. (NASDAQ:DVLT), presents today, Tuesday, September 15, at 3:30 PM ET at the Lotte New York Palace Hotel in New York City.Datavault AI Inc.…
-
1 month ago benzinga.com
Clene Prices Registered Direct Offering Of 1,219,513 Shares At $3.28/Shr To Existing Shareholders With Total Gross Proceeds Of $4M
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million…
1 month ago globenewswire.com
Clene Announces $4 Million Registered Direct Offering
Investment led by Clene's Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene's Chief Executive Officer and other existing shareholders $4 million…
1 month ago defenseworld.net
Canopy Growth (NASDAQ:CGC) vs. Clene (NASDAQ:CLNN) Financial Comparison
Canopy Growth (NASDAQ: CGC - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
1 month ago globenewswire.com
Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C.
2 months ago marketbeat.com
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses
Clene NASDAQ: CLNN is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses…
2 months ago globenewswire.com
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The…
2 months ago globenewswire.com
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August…
2 months ago zacks.com
Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.78 per share a year ago.
2 months ago globenewswire.com
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in…
2 months ago marketbeat.com
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS
Clene NASDAQ: CLNN said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of…
3 months ago globenewswire.com
Clene to Present at The Canaccord 46th Annual Growth Conference
SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage…
5 months ago zacks.com
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Clene (CLNN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall…
5 months ago zacks.com
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.5 per share a year ago.
-
5 months ago benzinga.com
Clene Q1 EPS $(0.69) Misses $(0.66) Estimate, Sales $15.000K Miss $35.064K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.66) by 4.55 percent. This is a 666.67 percent decrease over losses of $(0.09) per…
5 months ago globenewswire.com
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an…
6 months ago globenewswire.com
Clene Announces $7 Million Underwritten Offering of Common Stock
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
6 months ago benzinga.com
Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug
FDA signals accelerated pathway for Clene's ALS drug CNM-Au8, with NDA filing planned and mixed technical indicators in focus.
6 months ago benzinga.com
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets
Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels highlight momentum and key price zones.
-
6 months ago benzinga.com
Clene Announces FDA Approves Propose Data To Be Capable for Submission, Review Of New Drug Application For Pathway To Treat Amyotrophic Lateral Sclerosis
Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the…
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
7 months ago benzinga.com
Clene Q4 EPS $(0.88) Misses $(0.56) Estimate, Sales $77.000K Beat $49.000K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.56) by 57.99 percent. This is a 47.31 percent increase over losses of $(1.67) per…
-
9 months ago benzinga.com
Clene Announces FDA Grants In-Person Type C Meeting In Q1 2026 As New Analyses Support NfL Reduction And CNM‑Au8 Biomarker Findings Linked To Lower ALS Mortality Risk
The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are…
-
9 months ago benzinga.com
Clene Commences $28M Offering Of Securities
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
11 months ago benzinga.com
Clene Completes FDA-Recommended Biomarker Analyses For CNM-Au8 In Patients With Amyotrophic Lateral Sclerosis; Data Shows Reductions In Neurofilament Light, Glial Fibrillary Acidic Protein
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on…
-
11 months ago benzinga.com
Clene To Update Investors On CNM-Au8 ALS Program In December 3 Webcast At 8:30am ET
Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
11 months ago benzinga.com
Clene Q3 EPS $(0.85) Misses $(0.58) Estimate, Sales $15.000K Miss $55.143K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.58) by 46.55 percent. This is a 30.33 percent increase over losses of $(1.22) per…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ: CLNN) with a Buy and maintains $23 price target.
-
1 year ago benzinga.com
Benchmark Maintains Buy on Clene, Lowers Price Target to $31
Benchmark analyst Bruce D. Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $33 to $31.
-
1 year ago benzinga.com
Clene Inc Announces New Preclinical Data Showing That Its Lead Candidate, CNM-Au8, Improved Cellular Health In A Dopaminergic Neuron Model Of Parkinson's Disease
Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize…
-
1 year ago benzinga.com
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
Canaccord Genuity Maintains Buy on Clene, Lowers Price Target to $48
Canaccord Genuity analyst Sumant Kulkarni maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $83 to $48.
-
1 year ago benzinga.com
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
-
1 year ago benzinga.com
Clene Q2 EPS $(0.78) Misses $(0.47) Estimate, Sales $27.000K Miss $52.833K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.47) by 64.9 percent. This is a 26.42 percent increase over losses of $(1.06) per…